Hsiao-Wu Hsieh
Hsiao-Wu Hsieh has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Daniel J. Griffin
Pivotal & Commercial Synthetics, Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
5 shared publications - Matthew G. Beaver
Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
4 shared publications Alicia Zeng
Pivotal Attribute Sciences, Amgen, Inc., Cambridge, Massachusetts 02142, United States
3 shared publications- Derek B. Brown
Pivotal and Commercial Synthetics, Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
3 shared publications Nandini Sarkar
Pivotal Attribute Sciences, Amgen, Inc., Cambridge, Massachusetts 02142, United States
3 shared publications- Oliver R. Thiel
Chemical Process Research & Development, Amgen, Inc. One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (USA)
3 shared publications
Latest Publications
- 2 June 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1456-1464
Development of an Improved Process To Prepare a Key Intermediate in the Manufacture of Sotorasib
- 2 June 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1456-1464
Development of an Improved Process To Prepare a Key Intermediate in the Manufacture of Sotorasib
- 25 June 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (7) , 2844-2853
PAT-Enabled Automated Feedforward Control: An Application to the Continuous Manufacture of Apremilast
- 25 June 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (7) , 2844-2853
PAT-Enabled Automated Feedforward Control: An Application to the Continuous Manufacture of Apremilast
- 13 February 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (5) , 1385-1401
A Continuous Process for Manufacturing Apremilast. Part II: Process Characterization to Establish a Parametric Control Strategy
- 13 February 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (5) , 1385-1401
A Continuous Process for Manufacturing Apremilast. Part II: Process Characterization to Establish a Parametric Control Strategy
- 2 February 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (5) , 1369-1384
A Continuous Process for Manufacturing Apremilast. Part I: Process Development and Intensification by Utilizing Flow Chemistry Principles
- 2 February 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (5) , 1369-1384
A Continuous Process for Manufacturing Apremilast. Part I: Process Development and Intensification by Utilizing Flow Chemistry Principles
- 19 October 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (11) , 3115-3125
Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
- 19 October 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (11) , 3115-3125
Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
- Open Access
Anomeric O-Functionalization of Carbohydrates for Chemical Conjugation to Vaccine Constructs
Carbohydrates mediate a wide range of biological interactions, and understanding these processes benefits the development of new therapeutics. Isolating sufficient quantities of glycoconjugates from biological samples remains a significant challenge. With advances in chemical and enzymatic carbohydrate synthesis, the availability of complex carbohydrates is increasing and developing methods for stereoselective conjugation these polar head groups to proteins and lipids is critically important for pharmaceutical applications. The aim of this review is to provide an overview of commonly employed strategies for installing a functionalized linker at the anomeric position as well as examples of further transformations that have successfully led to glycoconjugation to vaccine constructs for biological evaluation as carbohydrate-based therapeutics.
Open AccessAnomeric O-Functionalization of Carbohydrates for Chemical Conjugation to Vaccine Constructs
Carbohydrates mediate a wide range of biological interactions, and understanding these processes benefits the development of new therapeutics. Isolating sufficient quantities of glycoconjugates from biological samples remains a significant challenge. With advances in chemical and enzymatic carbohydrate synthesis, the availability of complex carbohydrates is increasing and developing methods for stereoselective conjugation these polar head groups to proteins and lipids is critically important for pharmaceutical applications. The aim of this review is to provide an overview of commonly employed strategies for installing a functionalized linker at the anomeric position as well as examples of further transformations that have successfully led to glycoconjugation to vaccine constructs for biological evaluation as carbohydrate-based therapeutics.
- Open Access
- 25 June 2018
- Published by MDPI AG in Preprints.org
Anomeric Functionalization of Carbohydrates for Chemical Conjugation to Vaccine Constructs
Carbohydrates mediate a wide range of biological interactions, and understanding these processes benefits the development of new therapeutics. Isolating sufficient quantities of glycoconjugates from biological samples remains a significant challenge. With advances in chemical and enzymatic carbohydrate synthesis, the availability of complex carbohydrates is increasing and developing methods for stereoselective conjugation these polar head groups to proteins and lipids is critically important for pharmaceutical applications. The aim of this review is to provide an overview of commonly employed strategies for installing a functionalized linker at the anomeric position as well as examples of further transformations that have successfully led to glycoconjugation to vaccine constructs for biological evaluation as carbohydrate-based therapeutics.
- 25 June 2018
- Published by MDPI AG in Preprints.org
Open AccessAnomeric Functionalization of Carbohydrates for Chemical Conjugation to Vaccine Constructs
Carbohydrates mediate a wide range of biological interactions, and understanding these processes benefits the development of new therapeutics. Isolating sufficient quantities of glycoconjugates from biological samples remains a significant challenge. With advances in chemical and enzymatic carbohydrate synthesis, the availability of complex carbohydrates is increasing and developing methods for stereoselective conjugation these polar head groups to proteins and lipids is critically important for pharmaceutical applications. The aim of this review is to provide an overview of commonly employed strategies for installing a functionalized linker at the anomeric position as well as examples of further transformations that have successfully led to glycoconjugation to vaccine constructs for biological evaluation as carbohydrate-based therapeutics.